Astrazeneca vs Thermo Fisher Scientific: Fair Value & Quality
Both stocks run through our 21 valuation models. Here is how Astrazeneca (AZN) and Thermo Fisher Scientific (TMO) compare, as of Jul 23, 2026.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Astrazeneca · Health Care
Thermo Fisher Scientific · Health Care
Bottom line
As of Jul 23, 2026, Fair Value Calculator sees Astrazeneca as the more attractively valued of the two: Astrazeneca trades at $169 versus a fair value of $130 (-24%), while Thermo Fisher Scientific trades at $523 versus $308 (-41%).
Astrazeneca has the higher quality score (67/100).
See the full analysis →See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models, not a recommendation and not financial advice. Values change with price and fundamentals; the date shown above applies.